David Carroll Biography and Net Worth

CFO of IVERIC bio


David Francis Carroll is Chief Financial Officer, Senior Vice President, Treasurer of the Company. Mr. Carroll has served as our senior vice president, chief financial officer and treasurer since April 2017. Mr. Carroll joined us in June 2016 and previously served as senior vice president, finance from June 2016 to April 2017. Prior to joining us, Mr. Carroll served in several senior financial leadership roles at The Medicines Company from May 2008 to June 2016, including vice president, controller from October 2008 to December 2015 and senior vice president, chief accounting officer from January 2016 to June 2016. Earlier in his career, Mr. Carroll served in various financial management positions of increasing responsibility for Genentech, Inc., a member of the Roche Group, Novartis AG, and Bristol-Myers Squibb Company. Mr. Carroll is a certified public accountant and received a B.A. in economics from Ursinus College and an M.B.A. from Rutgers University.

What is David Francis Carroll's net worth?

The estimated net worth of David Francis Carroll is at least $2.74 million as of May 1st, 2023. Mr. Carroll owns 68,472 shares of IVERIC bio stock worth more than $2,735,456 as of March 28th. This net worth approximation does not reflect any other assets that Mr. Carroll may own. Additionally, Mr. Carroll receives an annual salary of $725,550.00 as CFO at IVERIC bio. Learn More about David Francis Carroll's net worth.

How old is David Francis Carroll?

Mr. Carroll is currently 57 years old. There are 5 older executives and no younger executives at IVERIC bio. The oldest executive at IVERIC bio is Mr. Glenn P. Sblendorio M.B.A., CEO & Director, who is 67 years old. Learn More on David Francis Carroll's age.

What is David Francis Carroll's salary?

As the CFO of IVERIC bio, Inc., Mr. Carroll earns $725,550.00 per year. There are 2 executives that earn more than Mr. Carroll. The highest earning executive at IVERIC bio is Mr. Glenn P. Sblendorio M.B.A., CEO & Director, who commands a salary of $1,360,000.00 per year. Learn More on David Francis Carroll's salary.

How do I contact David Francis Carroll?

The corporate mailing address for Mr. Carroll and other IVERIC bio executives is ONE PENN PLAZA 35TH FLOOR, NEW YORK NY, 10119. IVERIC bio can also be reached via phone at (609) 474-6755 and via email at [email protected]. Learn More on David Francis Carroll's contact information.

Has David Francis Carroll been buying or selling shares of IVERIC bio?

David Francis Carroll has not been actively trading shares of IVERIC bio over the course of the past ninety days. Most recently, David Francis Carroll sold 63,500 shares of the business's stock in a transaction on Monday, May 1st. The shares were sold at an average price of $37.04, for a transaction totalling $2,352,040.00. Following the completion of the sale, the chief financial officer now directly owns 68,472 shares of the company's stock, valued at $2,536,202.88. Learn More on David Francis Carroll's trading history.

Who are IVERIC bio's active insiders?

IVERIC bio's insider roster includes David Carroll (CFO), Pravin Dugel (EVP), Anthony Gibney (EVP), Calvin Roberts (Director), Glenn Sblendorio (CEO), Christopher Simms (SVP), and Keith Westby (COO). Learn More on IVERIC bio's active insiders.

Are insiders buying or selling shares of IVERIC bio?

During the last year, insiders at the sold shares 9 times. They sold a total of 233,500 shares worth more than $7,820,270.65. The most recent insider tranaction occured on July, 3rd when COO Keith Westby sold 20,000 shares worth more than $789,000.00. Insiders at IVERIC bio own 2.7% of the company. Learn More about insider trades at IVERIC bio.

Information on this page was last updated on 7/3/2023.

David Francis Carroll Insider Trading History at IVERIC bio

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/1/2023Sell63,500$37.04$2,352,040.0068,472View SEC Filing Icon  
4/24/2023Sell48,171$30.21$1,455,245.9168,472View SEC Filing Icon  
4/21/2023Sell1,829$30.00$54,870.0068,472View SEC Filing Icon  
1/3/2023Sell3,602$20.06$72,256.1268,472View SEC Filing Icon  
12/19/2022Sell5,671$21.51$121,983.2163,324View SEC Filing Icon  
12/12/2022Sell3,946$20.89$82,431.9447,052View SEC Filing Icon  
4/5/2022Sell4,684$19.01$89,042.8440,166View SEC Filing Icon  
4/1/2022Sell2,144$17.00$36,448.0040,166View SEC Filing Icon  
3/25/2022Sell16,772$17.02$285,459.44View SEC Filing Icon  
3/18/2022Sell11,561$17.00$196,537.00View SEC Filing Icon  
1/3/2022Sell15,819$16.39$259,273.41View SEC Filing Icon  
12/20/2021Sell6,710$15.44$103,602.40View SEC Filing Icon  
12/13/2021Sell5,836$14.74$86,022.64View SEC Filing Icon  
7/2/2019Sell2,773$1.25$3,466.25View SEC Filing Icon  
See Full Table

David Francis Carroll Buying and Selling Activity at IVERIC bio

This chart shows David Francis Carroll's buying and selling at IVERIC bio by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

IVERIC bio Company Overview

IVERIC bio logo
IVERIC bio, Inc., a biopharmaceutical company, focuses on the discovery and development of novel treatments for retinal diseases with unmet medical needs. The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD); and STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of autosomal recessive Stargardt disease. Its preclinical product candidatures include IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases. The company also develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of avacincaptad pegol (ACP) administered as a monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of ACP administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. In addition, its minigene programs comprises miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related inherited retinal diseases (IRDs). The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. The company was incorporated in 2007 and is based in Parsippany, New Jersey. As of July 11, 2023, IVERIC bio, Inc. operates as a subsidiary of Astellas US Holding, Inc.
Read More

Today's Range

Now: $39.95
Low: $39.95
High: $39.95

50 Day Range

MA: $38.88
Low: $36.90
High: $39.95

2 Week Range

Now: $39.95
Low: $9.39
High: $39.99

Volume

N/A

Average Volume

3,616,141 shs

Market Capitalization

$5.50 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.06